A new trading day began on Friday, with Alx Oncology Holdings Inc (NASDAQ: ALXO) stock price down -4.61% from the previous day of trading, before settling in for the closing price of $2.17. ALXO’s price has ranged from $1.88 to $17.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -8.67% over the past five years. Meanwhile, its annual earnings per share averaged 18.63%. With a float of $30.21 million, this company’s outstanding shares have now reached $49.95 million.
Let’s look at the performance matrix of the company that is accounted for 72 employees.
Alx Oncology Holdings Inc (ALXO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Alx Oncology Holdings Inc is 42.64%, while institutional ownership is 71.65%. The most recent insider transaction that took place on Aug 14 ’24, was worth 1,455. In this transaction SVP, FINANCE AND CAO of this company sold 564 shares at a rate of $2.58, taking the stock ownership to the 91,549 shares. Before that another transaction happened on Aug 14 ’24, when Company’s CHIEF MEDICAL OFFICER sold 1,365 for $2.58, making the entire transaction worth $3,522. This insider now owns 325,711 shares in total.
Alx Oncology Holdings Inc (ALXO) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -1.24 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.63% per share during the next fiscal year.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Trading Performance Indicators
Here are Alx Oncology Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.64, a number that is poised to hit -0.78 in the next quarter and is forecasted to reach -2.88 in one year’s time.
Technical Analysis of Alx Oncology Holdings Inc (ALXO)
Alx Oncology Holdings Inc (NASDAQ: ALXO) saw its 5-day average volume 0.51 million, a negative change from its year-to-date volume of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 43.91%. Additionally, its Average True Range was 0.21.
During the past 100 days, Alx Oncology Holdings Inc’s (ALXO) raw stochastic average was set at 1.19%, which indicates a significant decrease from 39.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.31% in the past 14 days, which was lower than the 120.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.55, while its 200-day Moving Average is $10.45. Nevertheless, the first resistance level for the watch stands at $2.17 in the near term. At $2.27, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.32. If the price goes on to break the first support level at $2.01, it is likely to go to the next support level at $1.96. Assuming the price breaks the second support level, the third support level stands at $1.86.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Key Stats
With a market capitalization of 109.03 million, the company has a total of 52,100K Shares Outstanding. Currently, annual sales are 0 K while annual income is -160,810 K. The company’s previous quarter sales were 0 K while its latest quarter income was -39,400 K.
